Precision BioSciences' PBGENE-HBV Hits 100% pgRNA Clearance at 0.4 mg/kg, Moves to Phase 2
DTIL has more than doubled off its 52-week low of $3.53.
Summary
Precision BioSciences reported Phase 1 hepatitis B data showing undetectable pgRNA in 100% of evaluable patients at the 0.4 mg/kg go-forward dose, plus biopsy evidence of cccDNA reduction, and said it is advancing to a global Phase 2. Its DMD program also cleared a DSMB safety review.
Key Events · Product Development and Regulatory · DTIL
-
PBGENE-HBV Clears pgRNA at Go-Forward Dose
11 of 12 evaluable patients (92%) reached undetectable pgRNA, including all six evaluable at 0.4 mg/kg; the lone holdout had a 95% reduction after only two 0.65 mg/kg doses.
-
Biopsies Show cccDNA Reduction
Paired liver biopsies at 0.4 mg/kg showed roughly 1-log (10-fold) and 1.5-log (35-fold) reductions in cccDNA, reproducing earlier EASL 2026 findings.
-
Phase 2 Dose Selected, Dosing Q1 2027
0.4 mg/kg chosen for the global ELIMINATE-B2 Phase 2 study, testing monotherapy and combination with an ASO; dosing expected to begin Q1 2027 with initial open-label data in H2 2027.
-
DMD Program Clears DSMB Review
First PBGENE-DMD patient completed eight weeks with no serious adverse events or adverse events of special interest; the DSMB endorsed dosing additional patients in Part 1.
Analysis · DTIL · Life Sciences
This is the first hard efficacy readout on PBGENE-HBV, the company's wholly owned hepatitis B program and the main driver of its valuation. At the 0.4 mg/kg go-forward dose, all six evaluable patients cleared pgRNA to undetectable, and paired liver biopsies showed 1-log to 1.5-log cccDNA reductions — direct evidence the drug does what it was designed to do. The first HBeAg-positive patient, a population with 2-3 log higher cccDNA burden, also cleared pgRNA from a 3.7-log baseline. With no dose-limiting toxicities across 59 administrations, the company has picked 0.4 mg/kg for a global Phase 2 (ELIMINATE-B2) with dosing expected in Q1 2027. Separately, the DMD program cleared its first safety hurdle: the DSMB endorsed dosing more patients after the first patient finished eight weeks with no serious adverse events. Both programs now have a funded path (cash runway guided through 2028), so the next real test is whether Phase 2 cure rates hold up in H2 2027.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DTIL was trading at $8.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $226.8M. The 52-week trading range was $3.53 to $9.62. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.